Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
6
×
boston blog main
life sciences
national blog main
boston top stories
biotech
national top stories
avapritinib
blueprint medicines
clinical trials
roche
cancer
deals
eli lilly
europe blog main
europe top stories
fda
genentech
medullary thyroid cancer
non-small cell lung cancer
pralsetinib
san francisco blog main
san francisco top stories
selpercatinib
thyroid cancer
acute hepatic porphyrias
akin akinc
alnylam pharmaceuticals
aminolevulinic acid
andrew berens
biopharma
brexanalone
cancer drugs
capmatinib
clinical data
cstone pharmaceuticals
deciphera pharmaceuticals
depression
drugs
duchenne
What
approval
6
×
fda
drug
blueprint
cancer
medicine
medicines
ret
rna
roche
second
seek
therapeutics
therapy
address
ago
alnylam
announced
approves
betting
billion
biopharma
brexanalone
candidate
carries
certain
chasing
currently
deadly
deal
deciphera
depression
designed
duchenne
filing
forms
gene
genetic
gi
historic
Language
unset
Current search:
approval
×
boston
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug